A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy-Reference-Cited by-同舟云学术

A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy

Published:2019-03-01 Issue:3 Volume:80 Page:325-329
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Cohen Karen,Stewart Annemie,Kengne Andre P.,Leisegang Rory,Coetsee Marla,Maharaj Shavani,Dunn Liezl,Hislop Michael,van Zyl Gert,Meintjes Graeme,Maartens Gary

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference15 articles.

1. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis;Ajose;AIDS.,2012

2. Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens;Van Zyl;PLoS One.,2013

3. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa;Levison;PLoS One.,2012

4. Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting;Maiga;J Antimicrob Chemother.,2012

5. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa;El-Khatib;AIDS.,2010

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART;Southern African Journal of HIV Medicine;2024-04-26

2. Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings;Diagnostics;2023-06-29

3. Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial;Journal of the International AIDS Society;2022-06

4. HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa;Journal of Global Antimicrobial Resistance;2021-11

5. In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix;mBio;2020-12-22